Compare SAMG & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | BDTX |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.5M | 116.8M |
| IPO Year | 2012 | 2020 |
| Metric | SAMG | BDTX |
|---|---|---|
| Price | $14.40 | $2.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | 17.2K | ★ 584.4K |
| Earning Date | 06-19-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.94% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ 0.56 | 0.39 |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.62 | N/A |
| P/E Ratio | $25.71 | ★ $3.37 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.23 | $1.20 |
| 52 Week High | $16.97 | $4.94 |
| Indicator | SAMG | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.07 | 43.83 |
| Support Level | $13.41 | $1.93 |
| Resistance Level | $15.50 | $2.67 |
| Average True Range (ATR) | 0.46 | 0.13 |
| MACD | -0.13 | -0.01 |
| Stochastic Oscillator | 15.16 | 35.21 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.